Hydroxychloroquine (Indication Antiphospholipid Syndrom)

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13685
R53192		 Gerde, 2021 Preeclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Co-administration Indication HCQ: Antiphospholipid syndrome (APS) 1.40 [0.06;35.34] C 1/69   0/32 1 69
ref
S13706
R53361		 Latino, 2020 Early severe preeclampsia during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Antiphospholipid syndrome (APS) 0.14 [0.02;1.20] C 1/12   12/30 13 12
ref
S13674
R53128		 Ye, 2017 Early onset preeclampsia‐ eclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Co-administration Indication HCQ: Antiphospholipid syndrome (APS) 0.36 [0.14;0.96] C 6/126   17/141 23 126
ref
S13718
R53443		 Sciascia, 2016 Pre-eclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Antiphospholipid syndrome (APS) 0.20 [0.02;1.65] C 1/34   8/60 9 34
ref
Total 4 studies 0.32 [0.14;0.70] 46 241
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Gerde, 2021Gerde, 2021 1.40[0.06; 35.34]1696%ROB confusion: seriousROB selection: unclearROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Latino, 2020Latino, 2020 0.14[0.02; 1.20]131213%ROB confusion: criticalROB selection: criticalROB classification: unclearROB missing: lowROB mesure: unclearROB reporting: moderate Ye, 2017Ye, 2017 0.36[0.14; 0.96]2312667%ROB confusion: seriousROB selection: unclearROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Sciascia, 2016Sciascia, 2016 0.20[0.02; 1.65]93414%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 0.32[0.14; 0.70]462410.05.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.32[0.14; 0.70]462410%NAGerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.32[0.14; 0.70]462410%NAGerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 4 Tags Adjustment   - No  - No 0.32[0.14; 0.70]462410%NAGerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 4 Co-administrationCo-administration 0.41[0.16; 1.03]241950%NAGerde, 2021 Ye, 2017 2 Indication HCQ   - Antiphospholipid syndrome (APS)  - Antiphospholipid syndrome (APS) 0.32[0.14; 0.70]462410%NAGerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 4 All studiesAll studies 0.32[0.14; 0.70]462410%NAGerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 40.05.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.92.71.9770.000Gerde, 2021Latino, 2020Ye, 2017Sciascia, 2016

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.32[0.14; 0.70]462410%NAGerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 40.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period Clowse (Antiphospholipid syndrome)Clowse (Antiphospholipid syndrome) 0.60[0.28; 1.28]NA-whatever (meta-analysis)during pregnancy (anytime or not specified)studies-9 metaPregmetaPreg Out of scale0.32[0.14; 0.70]0%241--Gerde, 2021 Latino, 2020 Ye, 2017 Sciascia, 2016 40.510.01.0